Povidone-Iodine

also known as Betadine · PVP-I · PVI · Betadine7.5% · IVIEW-1201 · Polyvinylpyrrolidone-Iodine · PVP-Iodine · pyodine · +18 more

Other / unclassified

Developed for: COVID-19 · dental caries · urinary tract infection · infectious disease · viral conjunctivitis · appendicitis · bacterial conjunctivitis · blepharitis
+36 more
· chronic rhinosinusitis · endometritis · methicillin-resistant staphylococcus aureus infectious disease · pleural neoplasm · prosthesis-related infectious disease · Acanthamoeba keratitis · acne · bacterial infectious disease · bacteriuria · common wart · congestive heart failure · corneal ulcer · endophthalmitis · eye infectious disorder · fungal keratitis · gingivitis · neoplasm of esophagus · nosocomial infection · otomycosis · periodontitis · periodontitis, chronic, adult · periprosthetic joint infection · pleural empyema · puerperal infection · respiratory tract infectious disorder · skin infection · staphylococcus aureus infection · thymoma · viral respiratory tract infection · abscess · bacterial urinary tract infection · candidiasis · epidemic keratoconjunctivitis · necrotizing soft tissue infection · pneumothorax · tracheal disorder
Investigated by: 3M · University of Miami · Advantage Dental Services, LLC · Advantage Silver Dental Arrest, LLC · Alexandria University · Assiut University
+112 more
· Brigham and Women's Hospital · DR. MALA KHAN · IVIEW Therapeutics Inc. · Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center · McMaster University · National University Hospital, Singapore · Poitiers University Hospital · Research to Prevent Blindness · St. Paul's Hospital, Canada · The University of Texas Health Science Center, Houston · University of California, Los Angeles · University of Iowa · University of Pennsylvania · University of Virginia · University of Washington · Washington University School of Medicine · Yale University · Academic Medical Center - University of Amsterdam · Aga Khan University · Agency for Healthcare Research and Quality (AHRQ) · Altacor Ltd. · Antisepsia Central · Ataturk University · Avrio Health · Bangladesh Reference Institute of Chemical Measurements (BRICM) · Beni-Suef University · Boston Medical Center · Cairo University · Case Western Reserve University · Centers for Disease Control and Prevention · Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Corewell Health East · Dentaid SL · Dhaka Medical College · Emory Healthcare · Emory University · Erasmus Medical Center · Erzincan Military Hospital · FISABIO Foundation · Halodine LLC · Hasanuddin University · Hisar Intercontinental Hospital · Hospital Clínico Universitario de Valencia · Hospital Universitario Fundación Jiménez Díaz · Hospital Universitario General de Villalba · Hospital Universitario Infanta Elena · Hospital Universitario Virgen de la Arrixaca · Hospital de Clinicas de Porto Alegre · Indiana University · Islamic Science University of Malaysia · Joseph Eye Hospital · King Abdulaziz University · Kolokotrones Family Foundation · L.V. Prasad Eye Institute · Laurentius Hospital Roermond · Leiden University Medical Center · Loma Linda University · Loreen Herwaldt · Ludwig-Maximilians - University of Munich · Mahidol University · Marin L. Schweizer, PhD · Martin-Luther-University Halle-Wittenberg · Mashhad University of Medical Sciences · Meir Medical Center · Menoufia University · Metro Health, Michigan · Military Hospital of Tunis · Mohamed Mousa Mohamed Mousa · Mundipharma Pte Ltd. · NYU Langone Health · Nantes University Hospital · National Cheng-Kung University Hospital · National Taiwan University Hospital · Nikita Gupta · all 118 on the full record

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Approved	US (FDA)	E-Z SCRUB 201	—	1985-11-29	fda.gov ↗

Trials 92 · started per year

today

US approved 1985

198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 05 trials
Phase 0	NCT04457765	Apr 2021 → Sep 2022	—	Boston Medical Center	Withdrawn	No outcome recorded
Phase 0	NCT04449965	Jan → Aug 2021	COVID-19	St. Paul's Hospital, Canada	Terminated	No outcome recorded Stop: Enrollment
Phase 0	NCT04478019	Jul 2020 → Jun 2022	COVID-19	University of Wisconsin, Madison	Completed	No outcome recorded
Phase 0	NCT02990013	Dec 2018 → Dec 2019	toxic dermatosis	University of Miami	Completed	No outcome recorded
Phase 0	NCT04097613	Jul 2017 → Apr 2019	chronic rhinosinusitis	St. Paul's Hospital, Canada	Completed	No outcome recorded
Phase 15 trials
Phase 1	NCT06339294	Jun → Dec 2023	otomycosis	Rawalpindi Medical College	Completed	No outcome recorded
Phase 1	NCT04761133	Mar → Jul 2021	respiratory tract infectious disorder	Alexandria University	Completed	No outcome recorded
Phase 1	NCT04075526	Oct 2019 → Jan 2024	osteoarthritis	NYU Langone Health	Completed	No outcome recorded
Phase 1	NCT04039126	Jun 2019 → Dec 2020	pleural neoplasm	University College Hospital, Ibadan	Unknown	No outcome recorded
Phase 1	NCT02645617	Mar → Sep 2016	dental caries	Advantage Dental Services, LLC	Completed	No outcome recorded
Phase 1/23 trials · 1 missed
Phase 1/2	NCT04347954	Aug → Dec 2020	COVID-19	Stanford University	Completed	Missed primary
Phase 1/2	NCT04510402	Aug 2020 → Feb 2021	COVID-19, iodine hypothyroidism	Brigham and Women's Hospital	Unknown	No outcome recorded
Phase 1/2	NCT04371458	Jul 2020 → Jul 2025	thymoma	Yale University	Withdrawn	No outcome recorded
Phase 220 trials · 2 met primary · 2 missed
Phase 2	NCT05696132	Nov 2024 → Dec 2025	methicillin-resistant staphylococcus aureus infectious disease	Nantes University Hospital	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT06616207	Sep 2024 → Mar 2027 expected	gingivitis	University of Washington	Active not recruiting	No outcome recorded
Phase 2	NCT03749317	Feb 2023 → Apr 2024	viral conjunctivitis	IVIEW Therapeutics Inc.	Completed	No outcome recorded
Phase 2	NCT05816070	Jan → Nov 2023	bacterial conjunctivitis	IVIEW Therapeutics Inc.	Completed	Met primary
Phase 2	NCT05546762	Sep 2022 → Apr 2024	pleural empyema	Alexandria University	Completed	No outcome recorded
Phase 2	NCT05272254	Sep 2022 → May 2027 expected	dental caries	University of Rochester	Active not recruiting	No outcome recorded
Phase 2	NCT04947527	Jun 2022 → Jun 2024	dental caries	Advantage Silver Dental Arrest, LLC	Completed	Mixed
Phase 2	NCT05239598	Feb → Jul 2022	COVID-19	University of Pennsylvania	Completed	Missed primary
Phase 2	NCT04371965	Sep → Oct 2020	COVID-19	Poitiers University Hospital	Completed	No outcome recorded
Phase 2	NCT04549376	Jul → Oct 2020	COVID-19	DR. MALA KHAN	Completed	Met primary
Phase 2	NCT04410159	Jun 2020	COVID-19	Islamic Science University of Malaysia	Completed	No outcome recorded
Phase 2	NCT04364802	Apr 2020 → Jan 2022	COVID-19	Nikita Gupta	Completed	No outcome recorded
Phase 2	NCT04253912	Feb 2020 → Jan 2021	common wart	Veloce BioPharma LLC	Unknown	No outcome recorded
Phase 2	NCT03484507	Jan 2018 → Nov 2022	Acanthamoeba keratitis	University of California, San Francisco	Completed	Missed primary
Phase 2	NCT03101371	Oct 2017 → Feb 2019	prosthesis-related infectious disease, urinary tract infection	University of Colorado, Denver	Completed	No outcome recorded
Phase 2	NCT03082196	Mar 2017 → May 2019	dental caries	Advantage Dental Services, LLC	Completed	Mixed
Phase 2	NCT04183231	Nov 2016 → Feb 2017	dental caries	Advantage Silver Dental Arrest, LLC	Completed	No outcome recorded
Phase 2	NCT02664220	Apr 2016 → Mar 2018	appendicitis	The University of Texas Health Science Center, Houston	Completed	No outcome recorded
Phase 2	NCT02126709	Jun → Dec 2014	acne	National University Hospital, Singapore	Unknown	No outcome recorded
Phase 2	NCT00386958	Nov 2002 → Jan 2006	corneal ulcer	Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center	Completed	No outcome recorded

Phase 2/31 trial
Phase 2/3	NCT05895773	Jun → Nov 2023	—	Menoufia University	Completed	No outcome recorded
Phase 314 trials · 1 met primary · 1 missed
Phase 3	NCT06363877	Jun 2024 → Oct 2026 expected	—	Loma Linda University	Recruiting	No outcome recorded
Phase 3	NCT06302335	Jan 2023 → Dec 2027 expected	—	Hospital de Clinicas de Porto Alegre	Recruiting	No outcome recorded
Phase 3	NCT05084378	Mar 2022 → Aug 2024	periprosthetic joint infection	McMaster University	Completed	No outcome recorded
Phase 3	NCT05021315	Sep 2021 → Sep 2022	infective vaginitis, puerperal infection	Cairo University	Unknown	No outcome recorded
Phase 3	NCT04872686	Apr → May 2021	viral respiratory tract infection	DR. MALA KHAN	Completed	No outcome recorded
Phase 3	NCT04446104	May → Aug 2020	COVID-19	National University Hospital, Singapore	Completed	No outcome recorded
Phase 3	NCT04048356	Jul 2019 → Feb 2021	female reproductive system disorder, pelvic organ prolapse, urinary tract infection	University of New Mexico	Completed	Met primary
Phase 3	NCT02998554	Mar 2017 → May 2019	viral conjunctivitis	Shire	Terminated	No outcome recorded Stop: Business
Phase 3	NCT01531699	Feb → Oct 2012	infectious disease	Altacor Ltd.	Completed	No outcome recorded
Phase 3	NCT01700803	Jan → Apr 2012	—	Assiut University	Completed	No outcome recorded
Phase 3	NCT01321125	Apr → Dec 2011	infectious disease	University of Guanajuato	Completed	No outcome recorded
Phase 3	NCT00950027	Apr 2008 → Sep 2011	—	Rennes University Hospital	Terminated	Missed primary
Phase 3	NCT00516399	Mar 2008 → Sep 2010	fungal keratitis	University of California, Los Angeles	Terminated	No outcome recorded
Phase 3	NCT00500669	Jun 2004 → Dec 2013	skin infection, varicose disease	Royal Hobart Hospital	Terminated	No outcome recorded Stop: Enrollment

Phase 427 trials · 2 met primary · 2 missed
Phase 4	NCT04200729	Mar 2027 → Mar 2030 expected	appendicitis	The University of Texas Health Science Center, Houston	Not yet recruiting	No outcome recorded
Phase 4	NCT07707063	May 2026 → May 2027 expected	periodontitis	Military Hospital of Tunis	Recruiting	No outcome recorded
Phase 4	NCT07474194	Sep 2025 → Apr 2026 overdue	—	Beni-Suef University	Recruiting	No outcome recorded
Phase 4	NCT05745467	Jul 2024 → Jul 2025	COVID-19	University of Iowa	Withdrawn	No outcome recorded
Phase 4	NCT04941131	May → Jul 2023	COVID-19	King Abdulaziz University	Completed	Missed primary
Phase 4	NCT05763602	Sep 2022 → May 2026 overdue	—	Loreen Herwaldt	Active not recruiting	No outcome recorded
Phase 4	NCT05529173	Sep 2022 → Nov 2023	methicillin-resistant staphylococcus aureus infectious disease	Rutgers, The State University of New Jersey	Completed	Met primary
Phase 4	NCT05276687	Sep 2022 → Mar 2024	—	Assiut University	Unknown	No outcome recorded
Phase 4	NCT05049213	Jun → Aug 2022	COVID-19	National Taiwan University Hospital	Completed	No outcome recorded
Phase 4	NCT05946005	Dec 2021 → Apr 2022	—	Hasanuddin University	Completed	No outcome recorded
Phase 4	NCT05214196	Sep → Dec 2021	COVID-19	Ataturk University	Completed	No outcome recorded
Phase 4	NCT04981860	Aug 2021 → Dec 2025	bacterial conjunctivitis	University of Miami	Suspended	No outcome recorded
Phase 4	NCT04517188	Apr → Jul 2021	COVID-19	Halodine LLC	Unknown	No outcome recorded
Phase 4	NCT04745663	Feb → Apr 2021	eye infectious disorder	Norwegian University of Science and Technology	Terminated	No outcome recorded
Phase 4	NCT04210505	Sep 2020 → Jan 2024 overdue	staphylococcus aureus infection	Marin L. Schweizer, PhD	Active not recruiting	No outcome recorded
Phase 4	NCT04146116	Feb 2020 → Jun 2021	—	University of Iowa	Completed	No outcome recorded
Phase 4	NCT03757143	Jan → Sep 2019	—	Poitiers University Hospital	Completed	Met primary
Phase 4	NCT02975921	Jul 2018 → Sep 2020	congestive heart failure, pleural neoplasm	Yale University	Withdrawn	No outcome recorded
Phase 4	NCT03385304	Apr 2018 → Oct 2021	—	University of Maryland, Baltimore	Completed	Missed primary
Phase 4	NCT03447639	Mar → Oct 2018	prosthesis-related infectious disease, urinary tract infection	Corewell Health East	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT03133312	May → Dec 2017	bacterial infectious disease	Metro Health, Michigan	Completed	No outcome recorded
Phase 4	NCT02245334	Oct 2014 → Oct 2015	infectious disease, prostate disorder	Seoul National University Hospital	Unknown	No outcome recorded
Phase 4	NCT02032394	Jul 2013 → Feb 2014	bacteriuria, nosocomial infection, urinary tract infection	Mashhad University of Medical Sciences	Unknown	No outcome recorded
Phase 4	NCT01647347	Aug 2012 → Jul 2013	—	University of Zurich	Completed	No outcome recorded
Phase 4	NCT01437228	Oct 2010 → Mar 2011	endometritis	Erzincan Military Hospital	Completed	No outcome recorded
Phase 4	NCT00461656	Sep 2009 → Dec 2012	endophthalmitis, strabismus	Erasmus Medical Center	Completed	No outcome recorded
Phase 4	NCT01179412	Jul 2004 → Dec 2009	viral conjunctivitis	Mahidol University	Completed	No outcome recorded

Phase not applicable17 trials · 3 missed
—	NCT07715409	May 2027 expected	endometritis	Mohamed Mousa Mohamed Mousa	Not yet recruiting	No outcome recorded
—	NCT04341688	Dec 2021 → Jun 2022	COVID-19	Aga Khan University	Unknown	No outcome recorded
—	NCT07470242	Oct 2021 → Mar 2023	chronic rhinosinusitis	Pusan National University Hospital	Completed	No outcome recorded
—	NCT05160623	Aug 2021 → Dec 2022	blepharitis	Shaare Zedek Medical Center	Unknown	No outcome recorded
—	NCT05175027	May → Oct 2021	—	Hisar Intercontinental Hospital	Completed	No outcome recorded
—	NCT06284174	Jan 2021 → Dec 2024 overdue	—	National Cheng-Kung University Hospital	Recruiting	No outcome recorded
—	NCT04707742	Jun 2020 → Sep 2021	COVID-19	FISABIO Foundation	Completed	Missed primary
—	NCT03432975	Dec 2017 → Aug 2019	periodontitis, chronic, adult	Cliniques universitaires Saint-Luc- Université Catholique de Louvain	Unknown	No outcome recorded
—	NCT02676791	Feb 2016 → Sep 2021	neoplasm of esophagus	Technical University Dresden	Completed	No outcome recorded
—	NCT02424357	Jul 2015 → Jan 2016	strabismus	University of Miami	Completed	Missed primary
—	NCT02027324	Jun 2015 → Feb 2017	—	Brigham and Women's Hospital	Withdrawn	No outcome recorded
—	NCT02202577	Mar 2014 → Jul 2016	—	Case Western Reserve University	Completed	Missed primary
—	NCT01893060	Jul 2013 → May 2014	—	University of Virginia	Unknown	No outcome recorded
—	NCT01886001	Nov 2012 → May 2013	—	University of Virginia	Completed	No outcome recorded
—	NCT01560962	Jan → Dec 2012	blepharitis	Southern California Institute for Research and Education	Terminated	No outcome recorded
—	NCT01350713	Jul 2011 → Jul 2012	—	Meir Medical Center	Unknown	No outcome recorded
—	NCT00999427	Oct 2009 → Apr 2011	—	University of British Columbia	Completed	No outcome recorded

Comparator or background therapy69 trials
Phase 0	NCT03957291 Comparator	Aug 2019 → Aug 2022	—	Assiut University	Unknown	No outcome recorded
Phase 1	NCT04393792 Comparator	May 2020 → Mar 2022	COVID-19	Hampshire Hospitals NHS Foundation Trust	Unknown	No outcome recorded
Phase 1/2	NCT06906029 Comparator	Dec 2025 → Jul 2028 expected	abscess	University of Alabama at Birmingham	Active not recruiting	No outcome recorded
Phase 1/2	NCT04130451 Comparator	Oct → Dec 2019	pneumothorax	Dow University of Health Sciences	Unknown	No outcome recorded
Phase 1/2	NCT04041856 Comparator	Aug → Oct 2019	epidemic keratoconjunctivitis	Farabi Eye Hospital	Unknown	No outcome recorded
Phase 2	NCT02591251 Comparator	Oct 2015 → Mar 2016	—	Assiut University	Completed	No outcome recorded
Phase 2	NCT02396329 Comparator	Jun 2014 → Jun 2015	—	Ain Shams Maternity Hospital	Unknown	No outcome recorded
Phase 2	NCT01577524 Comparator	Jan 2012 → Jun 2016	—	Attabib, Najmedden, M.D.	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT00845819 Comparator	Feb 2009 → Oct 2014	chemotherapy-induced oral mucositis	Seoul National University Hospital	Completed	No outcome recorded
Phase 3	NCT07383402 Comparator	Mar 2026 → Dec 2027 expected	chronic rhinosinusitis	Amin Javer	Not yet recruiting	No outcome recorded
Phase 3	NCT05127525 Comparator	Nov 2021 → Jan 2022	angle-closure glaucoma, diabetic macular edema, occlusion of tributary of retinal vein	iRenix Medical, Inc.	Terminated	No outcome recorded
Phase 3	NCT03925155 Comparator	May 2020 → May 2022	—	Montefiore Medical Center	Withdrawn	No outcome recorded
Phase 3	NCT03700749 Comparator	Nov 2018 → Jul 2021	—	University of Birmingham	Unknown	No outcome recorded
Phase 3	NCT03004924 Comparator	Mar 2017 → Oct 2018	bacterial conjunctivitis	Shire	Completed	Missed primary
Phase 3	NCT02713074 Comparator	Oct 2016 → Mar 2017	—	Assiut University	Completed	No outcome recorded
Phase 3	NCT01481519 Comparator	Dec 2011 → Dec 2012	viral conjunctivitis	University of Campinas, Brazil	Completed	No outcome recorded
Phase 3	NCT01495117 Comparator	Oct 2011 → Oct 2014	—	Seung Duk Lee	Completed	No outcome recorded
Phase 3	NCT03062605 Comparator	May 2011 → Feb 2012	dental caries	University of California, Los Angeles	Completed	No outcome recorded
Phase 3	NCT00692484 Comparator	Oct 2007 → Feb 2008	—	C. R. Bard	Completed	No outcome recorded
Phase 3	NCT00335088 Background	Jun 2006 → May 2007	eye infectious disorder	HaEmek Medical Center, Israel	Unknown	No outcome recorded
Phase 3	NCT00231153 Comparator	Aug 2005 → Jun 2008	infectious disease	Cadence Pharmaceuticals	Completed	Missed primary
Phase 3	NCT00290290 Comparator	Sep 2003 → May 2008	—	Baylor College of Medicine	Completed	Met primary
Phase 4	NCT07044726 Comparator	Jun 2025 → May 2028 expected	bacterial urinary tract infection	University of Louisville	Recruiting	No outcome recorded
Phase 4	NCT06705842 Comparator	Apr 2025 → Jun 2026 overdue	appendicitis	The University of Texas Health Science Center, Houston	Recruiting	No outcome recorded
Phase 4	NCT06744907 Comparator	Jan → Nov 2025 overdue	—	Akron Children's Hospital	Recruiting	No outcome recorded
Phase 4	NCT06282510 Comparator	Jan 2024 → Dec 2026 expected	candidiasis	Mary K Hayden	Recruiting	No outcome recorded
Phase 4	NCT05919888 Comparator	Jun → Nov 2023	periprosthetic joint infection	St. Louis University	Completed	No outcome recorded
Phase 4	NCT05077592 Comparator	Sep → Dec 2021	—	Ain Shams University	Unknown	No outcome recorded
Phase 4	NCT04721457 Comparator	Jan → Mar 2021	COVID-19	King Abdulaziz University	Completed	No outcome recorded
Phase 4	NCT04603794 Comparator	Oct → Nov 2020	COVID-19	Ohio State University	Unknown	No outcome recorded
Phase 4	NCT03560193 Comparator	Sep 2018 → May 2022	—	Poitiers University Hospital	Completed	Missed primary
Phase 4	NCT03685604 Comparator	Sep 2018 → Jun 2020	—	University Hospital, Basel, Switzerland	Completed	No outcome recorded
Phase 4	NCT03348917 Comparator	Dec 2017 → Jan 2018	—	Mundipharma Manufacturing Pte Ltd.	Completed	No outcome recorded
Phase 4	NCT03349515 Comparator	Nov 2017 → Sep 2018	strabismus	Medical University of South Carolina	Completed	No outcome recorded
Phase 4	NCT03305159 Comparator	Aug 2017 → Apr 2018	—	Northwestern University	Completed	No outcome recorded
Phase 4	NCT02527512 Comparator	Jul 2017 → Feb 2019	necrotizing soft tissue infection	Boston Children's Hospital	Completed	No outcome recorded
Phase 4	NCT03118232 Comparator	Apr 2017 → Oct 2023	infectious disease	University of California, Irvine	Completed	No outcome recorded
Phase 4	NCT03014778 Comparator	Jan 2017 → Dec 2018	—	HaEmek Medical Center, Israel	Unknown	No outcome recorded
Phase 4	NCT02693483 Comparator	Apr 2015 → Jun 2016	puerperal infection	Ain Shams Maternity Hospital	Unknown	No outcome recorded
Phase 4	NCT02116608 Comparator	Sep 2014 → Sep 2019	tracheal disorder	University of Colorado, Denver	Completed	No outcome recorded
Phase 4	NCT02479347 Comparator	Mar 2013 → Sep 2016	breast neoplasm, skin infection	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano	Completed	No outcome recorded
Phase 4	NCT01919593 Comparator	Jan → Dec 2012	bacterial infectious disease	Thammasat University	Completed	No outcome recorded
Phase 4	NCT01313182 Comparator	Mar 2011 → Sep 2012	—	Solventum US LLC	Completed	No outcome recorded
Phase 4	NCT01184196 Comparator	Nov 2009 → Dec 2012	osteoarthritis, knee	Central DuPage Hospital	Terminated	No outcome recorded
—	NCT07460297 Background	Apr 2025 → Jan 2028 expected	—	Jianyi Li	Enrolling by invitation	No outcome recorded
—	NCT07295210 Comparator	Dec 2024 → Dec 2025	otomycosis	Mansoura University	Completed	No outcome recorded
—	NCT07801157 Background	Jul 2024 → Dec 2025	—	Mansoura University	Completed	No outcome recorded
—	NCT06400082 Comparator	Apr 2023 → Oct 2024 overdue	type 2 diabetes mellitus	Cairo University	Active not recruiting	No outcome recorded
—	NCT06595823 Comparator	Mar 2022 → Mar 2023	—	Egymedicalpedia	Completed	No outcome recorded
—	NCT05422703 Background	Jan → Jun 2022	temporomandibular joint dysfunction syndrome	Cairo University	Completed	No outcome recorded
—	NCT07155408 Background	Dec 2021 → May 2022	androgenetic alopecia	Elif Asena KANTARCI	Completed	No outcome recorded
—	NCT05122169 Comparator	Dec 2021 → Dec 2025	—	Seoul National University Hospital	Unknown	No outcome recorded
—	NCT06950229 Comparator	Oct 2020 → Mar 2021	—	Federal Teaching Hospital Abakaliki	Completed	No outcome recorded
—	NCT06936475 Comparator	Jun → Sep 2020	endometritis	Federal Teaching Hospital Abakaliki	Completed	No outcome recorded
—	NCT04278950 Comparator	Feb 2020 → Feb 2021	chronic rhinosinusitis	St. Paul's Hospital, Canada	Unknown	No outcome recorded
—	NCT03173053 Comparator	Feb 2018 → Oct 2021	movement disorder, staphylococcus aureus infection	Radboud University Medical Center	Terminated	No outcome recorded
—	NCT03549702 Comparator	Jan 2017 → Feb 2018	—	Ain Shams University	Completed	No outcome recorded
—	NCT02950246 Comparator	Nov 2016 → Jul 2018	prosthesis-related infectious disease	Hôpital Raymond Poincaré	Unknown	Met primary
—	NCT02868372 Comparator	Sep 2016 → Mar 2017	skin infection	Assiut University	Unknown	No outcome recorded
—	NCT02472223 Comparator	Mar 2015 → Jun 2018	viral conjunctivitis	Washington University School of Medicine	Completed	No outcome recorded
—	NCT02337972 Background	Jan → Dec 2015	diabetic macular edema	Sheba Medical Center	Unknown	No outcome recorded
—	NCT04169919 Comparator	Nov 2014 → Oct 2018	—	Minia University	Completed	No outcome recorded
—	NCT00896402 Comparator	Jul 2014 → Jan 2015	infectious disease	Northwell Health	Withdrawn	No outcome recorded Stop: Business
—	NCT02391714 Background	Oct 2013 → Aug 2014	—	University of New Mexico	Completed	No outcome recorded
—	NCT01898728 Comparator	Dec 2012 → Aug 2013	cataract	McMaster University	Completed	No outcome recorded
—	NCT01472549 Comparator	Sep 2011 → Jun 2015	—	Washington University School of Medicine	Completed	Met primary
—	NCT01619137 Comparator	Aug 2011 → Oct 2012	—	Aida Najafian	Unknown	No outcome recorded
—	NCT01216761 Comparator	May 2008 → Sep 2009	bacterial infectious disease	University of Michigan	Completed	No outcome recorded
—	NCT02652325 Comparator	? → Feb 2016	—	Rothman Institute Orthopaedics	Unknown	No outcome recorded

News releases announcing trial results or a regulatory action · 6

Date	Issuer	Release
2026-05-15	IVIEW Therapeutics Inc.	Results IVIEW Therapeutics Showcases Robust Pipeline at Eyecelerator and ARVO 2026, Highlighting Clinical Advances in Dry Eye, Viral Conjunctivitis, Glaucoma Gene Therapy, and Ocular Inflammation Treatment iviewtherapeutics.com ↗ The presentation featured drug’s sustained release of an efficacious dose, favorable PK bridging, and acceptable ocular tolerability enables the initiation of pivotal trials to simultaneously target the infectious and inflammatory components of acute adenoviral conjunctivitis.
2025-10-13	IVIEW Therapeutics Inc.	Regulatory Health Canada Issues “No Objection Letter” for Clinical Trial Application Evaluating Povidone Iodine-Budesonide Gel Forming Suspension in Patients Undergoing Endoscopic Sinus Surgery iviewtherapeutics.com ↗ IVIEW Therapeutics today announced that Health Canada has issued a No Objection Letter (NOL) for the proposed clinical trial titled “Evaluation of Povidone Iodine (PVP-I) + Budesonide Gel Forming Suspension Following Endoscopic Sinus Surgery (ESS).”
2024-02-28	IVIEW Therapeutics Inc.	Results IVIEW Announces Presentation of Positive Topline Results in Phase II Clinical Study of IVIEW-1201 for the Treatment of Bacterial Conjunctivitis at ARVO 2024 iviewtherapeutics.com ↗ The prespecified primary endpoint (clinical cure rate at Day 8) of non-inferiority to Ofloxacin achieved.
2023-05-20	IVIEW Therapeutics Inc.	Results IVIEW announces successful completion of in-vitro virucidal study of IVIEW-1503, a safe, non-toxic and long-lasting Povidone Iodine nasal spray for the prevention and treatment of COVID-19 iviewtherapeutics.com ↗ The results have evidently demonstrated IVIEW-1503 as a potential virucidal agent in preventing and treating SARS-CoV-2 viral infection.
2021-04-28	Mundipharma Research Limited	Results Large-scale study shows oral hydroxychloroquine and povidone-iodine throat spray can reduce spread of Covid-19 in high transmission settings mundipharma.com ↗
2020-09-16	IVIEW Therapeutics Inc.	Regulatory IVIEW Collaboration with Dr. Amin Javer at St. Paul’s Hospital and Sinus Centre, University of British Columbia, Canada to study Povidone Iodine formulations including IVIEW-1503, a long-lasting Povidone Iodine nasal spray for the treatment of COVID-19 iviewtherapeutics.com ↗ Health Canada has offered Dr. Amin Javer, a renowned rhinologist at the St. Paul’s Sinus Centre, University of British Columbia, Canada, a notification of Authorization for Clinical Trial Application of povidone iodine (PVP-I) formulations

All press releases naming this drug 11 releases

Date	Issuer	Release
2026-05-15	IVIEW Therapeutics Inc.	IVIEW Therapeutics Showcases Robust Pipeline at Eyecelerator and ARVO 2026, Highlighting Clinical Advances in Dry Eye, Viral Conjunctivitis, Glaucoma Gene Therapy, and Ocular Inflammation Treatment iviewtherapeutics.com ↗
2025-10-13	IVIEW Therapeutics Inc.	Health Canada Issues “No Objection Letter” for Clinical Trial Application Evaluating Povidone Iodine-Budesonide Gel Forming Suspension in Patients Undergoing Endoscopic Sinus Surgery iviewtherapeutics.com ↗
2024-02-28	IVIEW Therapeutics Inc.	IVIEW Announces Presentation of Positive Topline Results in Phase II Clinical Study of IVIEW-1201 for the Treatment of Bacterial Conjunctivitis at ARVO 2024 iviewtherapeutics.com ↗
2023-05-20	IVIEW Therapeutics Inc.	IVIEW announces successful completion of in-vitro virucidal study of IVIEW-1503, a safe, non-toxic and long-lasting Povidone Iodine nasal spray for the prevention and treatment of COVID-19 iviewtherapeutics.com ↗
2023-01-18	IVIEW Therapeutics Inc.	IVIEW announces Completion of First Patient Treatment in Phase II Clinical Study of IVIEW-1201 for the Treatment of Bacterial Conjunctivitis iviewtherapeutics.com ↗
2021-04-28	Mundipharma Research Limited	Large-scale study shows oral hydroxychloroquine and povidone-iodine throat spray can reduce spread of Covid-19 in high transmission settings mundipharma.com ↗
2020-09-16	IVIEW Therapeutics Inc.	IVIEW Collaboration with Dr. Amin Javer at St. Paul’s Hospital and Sinus Centre, University of British Columbia, Canada to study Povidone Iodine formulations including IVIEW-1503, a long-lasting Povidone Iodine nasal spray for the treatment of COVID-19 iviewtherapeutics.com ↗
2020-04-05	IVIEW Therapeutics Inc.	IVIEW is developing a safe, non-toxic and long-acting Povidone Iodine nasal spray for the prevention and treatment of COVID-19 infection to curb the COVID-19 spread iviewtherapeutics.com ↗
2019-12-19	IVIEW Therapeutics Inc.	IVIEW Announces First Patient Treated in Phase 2 Clinical Trial Program Evaluating iVIEW-1201 in Patients with Acute Adenoviral Conjunctivitis iviewtherapeutics.com ↗
2018-06-27	IVIEW Therapeutics Inc.	IVIEW Therapeutics Closes its A round financing to move forward IVW-1201, a novel sustain release povidone iodine gel forming solution, into phase II clinical trials for the treatment of adenoviral conjunctivitis iviewtherapeutics.com ↗
2018-03-26	IVIEW Therapeutics Inc.	IVIEW Therapeutics will present its novel sustained-release povidone iodine ophthalmic formulation for the treatment of acute conjunctivitis in TechConnect World Innovation Summit & Expo and US National Innovation Summit and National SBIR/STTR Conference iviewtherapeutics.com ↗

Evidence & citations 30 cited values

Every value below carries the sentence it was read from. 168 sources stand behind the page.

Field	Value	Cited text
Known as	povidone-iodine	“The purpose of this study is to see whether applying povidone iodine (PVI) to the noses of patients undergoing lower extremity (leg, ankle, or foot) orthopedic fixation...” NCT05763602 ↗ 163 “Three antiseptics will be tested: 2% chlorhexidine gluconate in 70% isopropyl alcohol, 10% sodium hypochlorite and 10% povidone-iodine, each one will be applied on the surface...” NCT01321125 ↗ “A Phase 2, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of IVIEW-1201 (1.0% Povidone-Iodine) Gel Forming Ophthalmic Solution...” NCT03749317 ↗ “Extraoral Bacitracin-Neomycin ointment and 10% povidone-iodine, together with intraoral benzydamine hydrochloride oral spray and chlorhexidine gluconate mouthwash, administered...” NCT07801157 ↗ “Participants instructed to instill 1 drop of SHP640 (Povidone-iodine \[PVP-I\] 0.6 percent \[%\] and Dexamethasone 0.1%) ophthalmic suspension in each eye 4 times daily (QID)...” NCT02998554 ↗ “In previous studies, povidone iodine (PVP-I), a widely used bactericidal antiseptic, and sodium fluoride (NaF), used to foster remineralization of enamel, were applied...” PMID 30938600 ↗ Apr 2018 “In order to assess the effect of Betadine (10% povidone-iodine) in the groin wound on infection rates and recurrence rates in patients undergoing primary varicose vein surgery...” NCT00500669 ↗ “MAIN RESULTS: We included 21 trials, reporting results for 7038 women evaluating the effects of vaginal cleansing (17 using povidone-iodine, 3 chlorhexidine, 1 benzalkonium...” PMID 32335895 ↗ Apr 2020 “Effect of oropharyngeal povidone-iodine preventive oral care on ventilator-associated pneumonia in severely brain-injured or cerebral hemorrhage patients: a multicenter,...” PMID 24105456 ↗ Jan 2014 “Vaginal preparation with povidone-iodine or chlorhexidine solution compared to saline or not cleansing immediately before cesarean delivery probably reduces the risk of...” PMID 30016540 ↗ Jul 2018 “Povidone iodine (PVP-I) is an alternative decolonization agent solutions and demonstrated rapid and superior bactericidal activity against MRSA in in vitro and ex vivo studies...” NCT05696132 ↗ Show 153 more sources
Known as	Betadiene	“0.2% Povidone-Iodine (Betadiene® by Aviro Health Inc./ Pyodine® by Brooks Pharma Inc.)” PMID 32928313 ↗ Sep 2020
Known as	Betadine	“250 ml solution of 2% povidone-iodine (i.e. 50 ml betadine in 200 ml saline) will be attached to the chest tube via a giving set and a 3-way tap and irrigated into the pleural...” NCT05546762 ↗ 14 “with sterile water (water that has been treated to remove bacteria and living organisms) vs Betadine also known as Povidone-Iodine (a medical grade cleaning solution)” NCT07044726 ↗ “ChloraPrep (2% chlorhexadine gluconate and 70% isopropyl alcohol) is superior to Betadine (10% povidone iodine) in reducing incision site bacterial colony counts.” NCT01184196 ↗ “Povidone Iodine (Betadine®) irrigation of subcutaneous tissue prior to skin closure” NCT03549702 ↗ “Treatment A = Betadine® 7.5% skin cleanser (PVP-I 7.5%)” NCT03348917 ↗ “0.2% Povidone-Iodine (BETADINE®) 10 ml gargle” NCT04341688 ↗ “0.35% povidone-iodine ("Betadine")” NCT02527512 ↗ “topical betadine (Povidone-iodine)” PMID 28549873 ↗ May 2017 NCT02116608 ↗ NCT02472223 ↗ NCT05276687 ↗ Show 4 more sources
Known as	Betadine 5%	“Povidone-Iodine 5% (PI; brand name: Betadine® 5%; Alcon, Fort Worth, TX), the antiseptic placed on the ocular surface prior to each injection.” NCT05127525 ↗
Known as	Betadine bucal 100 mg/ml	“Povidone-iodine 2% (Betadine© bucal 100 mg/ml) (Mylan Pharmaceuticals, S.L., Spain).” NCT04707742 ↗
Known as	Betadine7.5%	“The patients will be subjected to povidone-iodine (Betadine7.5%, Phama Care) for vaginal cleaning before the laparoscopic surgery” NCT02591251 ↗ 1 “The patients will be subjected to povidone-iodine (Betadine7.5%) for vaginal cleaning before office hysteroscopy” NCT02713074 ↗
Known as	Bétadine alcoolique	“Groupe A: (1) 5% (w/v) PVI-69% (v/v) ethanol (Bétadine alcoolique™, MEDA Pharma SAS); (2) InsyteTM AutoguardTM BC Winged, BD” NCT03757143 ↗
Known as	iodine	“Although povidone-iodine (iodine) is the only Food and Drug Administration-approved vaginal antiseptic solution, there is a lack of comparative data evaluating alternatives.” PMID 34973179 ↗ Dec 2021
Known as	Isodine Solucion	“The arm is composed of 10 human volunteers to test 2% chlorhexidine gluconate in 70% isopropyl alcohol (ChloraPrep ®, Enturia, Texas, USA ), hypochlorite 10% of electrochemical...” NCT01321125 ↗
Known as	IVIEW-1201	“A Phase 2, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of IVIEW-1201 (1.0% Povidone-Iodine) Gel Forming Ophthalmic Solution...” NCT03749317 ↗ 1 “IVIEW-1201 (1.0% Povidone-Iodine) Gel Forming Ophthalmic Solution” NCT05816070 ↗
Known as	P-I	“Povidone Iodine (P-I) scrub and paint” NCT02202577 ↗
Known as	Polividon- iyot	“%10 Polivinilpirolidon iyot (Polividon- iyot” NCT01437228 ↗
Known as	Polivinilpirolidon iyot	“%10 Polivinilpirolidon iyot (Polividon- iyot” NCT01437228 ↗
Known as	Polyvinylpyrrolidone-Iodine	“a polyvinylpyrrolidone-iodine (PVP-I; povidone-iodine) and NaF topical varnish was superior to one containing only NaF in prevention of new dental caries lesions” PMID 32437626 ↗ May 2020 1 “efficacy of topical 10% Polyvinylpyrrolidone-Iodine (PVPI) to prevent new caries lesions” NCT05272254 ↗
Known as	Povi-One	“Povi-One (10% povidone-iodine) will be applied topically by the graduate student to all tooth surfaces at the consultation appointment (baseline) before the placement of fixed...” NCT06616207 ↗
Known as	Povidine iodine	“with PI (povidine iodine) and AC (aqueous chlorhexidine).” NCT03957291 ↗
Known as	povidon iodine	“Drug: povidon iodine” NCT02950246 ↗
Known as	Povidone iodide	“Betadine (Povidone iodide) for reducing bacteria and patient discomfort in the eyes.” NCT04981860 ↗
Known as	Povidone-iodine 0.5% (Betadine) (PVP-I)	“Povidone-iodine 0.5% (Betadine) (PVP-I)” NCT05214196 ↗
Known as	Povidone-Iodine, USP 10% topical solution	“Povidone-Iodine, USP 10% topical solution” NCT00896402 ↗
Known as	PROFEND	“This study aims to evaluate the real-world effectiveness of nasal povidone-iodine (PROFEND®) in a group of 50 patients at the University of Iowa.” NCT04146116 ↗
Known as	PVI	“The purpose of this study is to see whether applying povidone iodine (PVI) to the noses of patients undergoing lower extremity (leg, ankle, or foot) orthopedic fixation...” NCT05763602 ↗ 6 “superiority of chlorhexidine (CHG)-alcohol over povidone iodine (PVI)-alcohol, the two most common alcohol-based antiseptic solutions used worldwide, is controversial.” PMID 31213447 ↗ Jun 2019 “Povidone-iodine (PVI) is an antiseptic solution consisting of polyvinylpyrrolidone with water, iodide, and 1% available iodine.” NCT02664220 ↗ “Povidone-iodine (PVI) is a widely used antimicrobial agent.” NCT05160623 ↗ “intra-abdominal irrigation with povidone-iodine (PVI)” NCT04200729 ↗ “5% povidone iodine (PVI)-69% ethanol” NCT03757143 ↗ “povidone-iodine (PVI) irrigation” NCT06705842 ↗
Known as	PVP-I	“Participants instructed to instill 1 drop of SHP640 (Povidone-iodine \[PVP-I\] 0.6 percent \[%\] and Dexamethasone 0.1%) ophthalmic suspension in each eye 4 times daily (QID)...” NCT02998554 ↗ 13 “In previous studies, povidone iodine (PVP-I), a widely used bactericidal antiseptic, and sodium fluoride (NaF), used to foster remineralization of enamel, were applied...” PMID 30938600 ↗ Apr 2018 “Povidone iodine (PVP-I) is an alternative decolonization agent solutions and demonstrated rapid and superior bactericidal activity against MRSA in in vitro and ex vivo studies...” NCT05696132 ↗ “1.25% Povidone-Iodine (PVP-I) (also known as betadine) to be used pre-procedure in the operating room via irrigation into the nasal cavity to act as viricidal preparation for...” NCT04457765 ↗ “Povidone-iodine (PVP-I) has broad antimicrobial and anti-inflammatory properties, while budesonide is a corticosteroid commonly used intranasally to reduce sinonasal inflammation.” NCT07383402 ↗ “a polyvinylpyrrolidone-iodine (PVP-I; povidone-iodine) and NaF topical varnish was superior to one containing only NaF in prevention of new dental caries lesions” PMID 32437626 ↗ May 2020 “Vigorously rinse with 15 ml of the 1% povidone-iodine (PVP-I) (Betadine Mouthwash/Gargle; Avrio Health LP, Stamford, CT, USA) for 30 s” NCT04721457 ↗ “Povidone-Iodine (PVP-I), common usage in otolaryngology operation and topical therapy, showed high virucidal properties” NCT05049213 ↗ “Povidone-iodine (PVP-I) is a broad-spectrum antiseptic with activity against bacteria, fungi, and viruses.” NCT04364802 ↗ “Phase I/II Trial of Povidone-iodine (PVP-I) Nasal Swab For Preventing COVID-19 Spread in Healthy Subjects” NCT04510402 ↗ “efficacy of topical 10% Polyvinylpyrrolidone-Iodine (PVPI) to prevent new caries lesions” NCT05272254 ↗ Show 3 more sources
Known as	PVP-Iodine	“SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension” NCT03004924 ↗ 1 NCT01647347 ↗
Known as	pyodine	“pyodine Povidone-iodine is a broad spectrum antiseptic for topical application in the treatment and prevention of wound infection.” NCT04130451 ↗ 1 “0.2% Povidone-Iodine (Betadiene® by Aviro Health Inc./ Pyodine® by Brooks Pharma Inc.)” PMID 32928313 ↗ Sep 2020
Known as	Repigel	“Name: Repigel Active ingredient: Povidone iodine Dosage form: Liposomal hydrogel Administration route: Topical Strength: 3%” NCT02126709 ↗
Known as	VBP-245	“Topical 2% Povidone-Iodine Gel (VBP-245) in Subjects With Verruca Vulgaris” NCT04253912 ↗
Action	Inhibit	“using Povidone-Iodine will reduce the the amount of virus in the nose and throat” NCT04393792 ↗
Modality	Other / unclassified	“widely used as an antiseptic agent” NCT01577524 ↗
Route	Topical	“treatment with topical povidone-iodine” NCT00231153 ↗